KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Return on Sales (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Return on Sales data on record, last reported at 3.84% in Q4 2025.

  • For Q4 2025, Return on Sales rose 359.0% year-over-year to 3.84%; the TTM value through Dec 2025 reached 1.25%, up 115.0%, while the annual FY2025 figure was 1.25%, 115.0% up from the prior year.
  • Return on Sales reached 3.84% in Q4 2025 per RIGL's latest filing, up from 0.4% in the prior quarter.
  • Across five years, Return on Sales topped out at 3.84% in Q4 2025 and bottomed at 1.64% in Q1 2022.
  • Average Return on Sales over 5 years is 0.04%, with a median of 0.12% recorded in 2023.
  • Peak YoY movement for Return on Sales: crashed -213bps in 2022, then skyrocketed 359bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 1.11% in 2021, then skyrocketed by 102bps to 0.03% in 2022, then decreased by -25bps to 0.02% in 2023, then skyrocketed by 1109bps to 0.25% in 2024, then soared by 1442bps to 3.84% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 3.84% in Q4 2025, 0.4% in Q3 2025, and 0.59% in Q2 2025.